Apyx Medical Inc (APYX) 2023 Q2 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Hello, and welcome, ladies and gentlemen, to the Second Quarter of Fiscal 2023 Earnings Conference Call for Apyx Medical Corporation. (Operator Instructions) Please note that this conference call is being recorded and that the recording will be available on the company's website for replay shortly.

    各位女士、先生,大家好,歡迎參加 Apyx Medical Corporation 2023 會計年度第二季財報電話會議。(接線員指示)請注意,本次電話會議將被錄音,錄音將於稍後提供於公司網站以供重播。

  • Before we begin, I would like to remind everyone that our remarks and responses to your questions today may contain forward-looking statements that are based on the current expectations of management and involve inherent risks and uncertainties that could cause actual results to differ materially from those indicated, including without limitation, those identified in the Risk Factors section of our most recent annual report on Form 10-K, our most recent 10-Q filing and the company's other filings with the Securities and Exchange Commission. Such factors may be updated from time to time in our filings with the SEC, which are available on our website. We undertake no obligation to publicly update or revise our forward-looking statements as a result of new information, future events or otherwise.

    在開始之前,我想提醒各位,我們今天的發言以及對各位提問的回應可能包含前瞻性陳述,該等陳述係基於管理層目前的預期,並涉及固有風險與不確定性,可能導致實際結果與所示內容存在重大差異,包括但不限於我們最近一期 Form 10-K 年度報告、最近一期 10-Q 季度申報以及公司向美國證券交易委員會(SEC)提交之其他文件中「風險因素」章節所識別者。相關因素可能會不時於我們向 SEC 提交的文件中更新,並可於我們的網站取得。我們不承擔因新資訊、未來事件或其他原因而公開更新或修訂任何前瞻性陳述之義務。

  • This call will also include references to certain financial measures that are not calculated in accordance with generally accepted accounting principles or GAAP. We generally refer to these as non-GAAP financial measures. Reconciliations of these non-GAAP financial measures to the most comparable measures calculated and presented in accordance with GAAP are available in the earnings press release on the Investor Relations portion of our website.

    本次電話會議亦將提及若干未依一般公認會計原則(GAAP)計算之財務衡量指標。我們通常將其稱為非 GAAP 財務衡量指標。該等非 GAAP 財務衡量指標與依 GAAP 計算並呈列之最可比衡量指標之調節表,已刊載於我們網站投資人關係專區的財報新聞稿中。

  • I would now like to turn the call over to Mr. Charlie Goodwin, Apyx Medical's President and Chief Executive Officer. Please go ahead, sir.

    現在我想把電話交給 Apyx Medical 總裁兼執行長 Charlie Goodwin 先生。先生,請開始。

  • Charles D. Goodwin - President, CEO & Director

    Charles D. Goodwin - President, CEO & Director

  • Thanks, operator, and welcome, everyone, to our second quarter of 2023 earnings call. I'm joined on today's call by our Chief Financial Officer, Tara Semb. Let me provide you with a brief outline of what we intend to cover today.

    謝謝接線員,也歡迎各位參加我們 2023 年第二季財報電話會議。今天與我一同出席的還有我們的財務長 Tara Semb。先讓我簡要說明今天我們預計涵蓋的內容。

  • I'll begin with a review of our Q2 revenue results and the factors that contributed to our sales performance. Then I'll walk through some of our key operational accomplishments during the quarter. Tara will discuss our financial results in detail along with our 2023 financial guidance, which we reaffirmed in our earnings release today. I'll then provide some closing remarks before we open the call for questions. With that, let's begin with a review of our revenue results.

    我將先回顧我們第二季營收結果以及促成銷售表現的因素,接著說明本季若干關鍵營運成果。Tara 將詳細說明我們的財務結果以及 2023 年財務指引;我們已在今天的財報新聞稿中重申該指引。之後我會做一些結語,並開放提問。那麼,我們先從營收結果回顧開始。

  • In the second quarter, we achieved total revenue growth of 32% year-over-year to $13.6 million. Our total revenue growth was driven by sales of our Advanced Energy products, which increased 40% year-over-year to $11.7 million. This growth performance was offset partially by OEM sales, which decreased 4% year-over-year to $1.8 million. Relative to the range of expectations that we provided for the second quarter, which we shared on our last earnings call, our OEM sales exceeded our expectations by approximately $400,000 and our Advanced Energy sales came in approximately $1.1 million below our expectations, driven primarily by softer-than-expected demand from our OUS distributors, which we believe is due in part to timing of orders.

    第二季,我們總營收年增 32%,達到 1,360 萬美元。總營收成長主要由我們先進能量(Advanced Energy)產品的銷售所帶動,該項年增 40% 至 1,170 萬美元。此成長表現部分被 OEM 銷售所抵銷,OEM 銷售年減 4% 至 180 萬美元。相較於我們在上一季財報電話會議中所分享、對第二季提供的預期區間,我們的 OEM 銷售較預期高出約 40 萬美元,而先進能量銷售則較預期低約 110 萬美元,主要原因是來自美國以外(OUS)經銷商的需求低於預期,我們認為部分與訂單時點有關。

  • Looking at our Advanced Energy sales results in more detail. While our global Advanced Energy sales performance continued to be impacted by the disruption related to the medical device safety communication that was originally posted by the FDA in March of 2022, we saw improving business trends during the second quarter. We were pleased to return to strong sales growth in the second quarter with Advanced Energy sales increasing 40% on a year-over-year basis and 21% on a quarter-over-quarter basis. On a year-over-year basis, we were pleased to achieve growth in the global sales of our generators and handpieces, both domestically and internationally.

    更進一步檢視我們的先進能量銷售結果。雖然我們全球先進能量銷售表現仍持續受到 FDA 於 2022 年 3 月最初發布之醫療器材安全通報相關干擾的影響,但我們在第二季看到業務趨勢改善。我們很高興第二季重回強勁的銷售成長,先進能量銷售年增 40%,季增 21%。以年增角度來看,我們很高興在國內與國際市場的發電機(generators)與手柄(handpieces)全球銷售皆實現成長。

  • In terms of our Advanced Energy performance in the U.S., sales of our Advanced Energy products to U.S. customers increased 38% year-over-year, consistent with our expectations for the quarter and represented the primary driver of our Advanced Energy sales performance. Our performance in the U.S. was driven primarily by sales of our generators due to a combination of growth in sales to both existing and new customers with contributions from handpiece sales as well. Most notably, we continue to see strong demand from our existing users following the U.S. launch of our next-generation Apyx One console at the beginning of 2023.

    就美國市場的先進能量表現而言,我們對美國客戶的先進能量產品銷售年增 38%,符合我們對本季的預期,並成為先進能量銷售表現的主要驅動因素。我們在美國的表現主要由發電機銷售帶動,原因在於對既有與新客戶的銷售皆成長,手柄銷售亦有所貢獻。最值得注意的是,自 2023 年初在美國推出我們的新一代 Apyx One 主機(console)以來,我們持續看到既有用戶的強勁需求。

  • As a reminder, we introduced an upgrade program that enables existing users to trade in their prior generation Renuvion generator in order to receive discounted pricing for our new Apyx One console. Importantly, we were pleased with our generator sales to new U.S. customers as well, particularly the uptick in adoption that we experienced following the updated safety communication in May. With respect to our Advanced Energy sales outside the U.S., while sales in all markets continue to be impacted by the safety communication, we were pleased to achieve strong international generator sales growth, which was the primary driver of our international performance.

    提醒各位,我們推出了一項升級方案,讓既有用戶可用上一代 Renuvion 發電機折抵換購,以折扣價格取得新的 Apyx One 主機。重要的是,我們也對新美國客戶的發電機銷售感到滿意,尤其是在 5 月更新安全通報後,我們看到採用率上升。至於美國以外的先進能量銷售,雖然所有市場的銷售仍持續受到安全通報影響,但我們很高興實現強勁的國際發電機銷售成長,這也是我們國際表現的主要驅動因素。

  • Our generator sales growth outside the U.S. was driven primarily by the distributor demand in multiple countries across Latin America and the Asia-Pacific region, which more than offset the year-over-year declines in our sales to distributors in Europe and the Middle East. This strong generator performance was moderated somewhat by modest growth in sales of handpieces to our OUS distributors, which we believe was influenced in part by the timing of orders during the quarter.

    我們在美國以外的發電機銷售成長,主要由拉丁美洲與亞太地區多個國家的經銷商需求所帶動,並且足以抵銷我們對歐洲與中東經銷商銷售的年減幅度。這項強勁的發電機表現,部分被我們對 OUS 經銷商的手柄銷售僅呈現溫和成長所稀釋;我們認為其中一部分亦受到本季訂單時點的影響。

  • In summary, the 40% growth, Advanced Energy growth we achieved in the second quarter was driven primarily by our sales performance in the U.S. Despite the headwinds we continue to experience related to the safety communication, we were pleased to see strong global sales of our Advanced Energy generators. And ultimately, I believe we made important progress, both domestically and internationally during the second quarter, positioning us for continued improvement as we progress through the remaining months of the year.

    總結而言,我們第二季達成的先進能量 40% 成長,主要由美國市場的銷售表現所驅動。儘管我們仍持續面臨與安全通報相關的不利因素,我們很高興看到先進能量發電機在全球的強勁銷售。最終,我相信我們在第二季於國內與國際市場都取得了重要進展,並在今年剩餘月份持續推進的過程中,為進一步改善奠定了基礎。

  • Moving to a discussion of our operational performance. In the second quarter, we made important progress on multiple fronts by continuing to expand the clinical indications for our Renuvion technology and address the remaining limitations of the safety communication, raise awareness of our recently secured clearances among surgeons and potential patients, advance our new product portfolio and enhance our balance sheet condition.

    接著談我們的營運表現。第二季,我們在多個面向取得重要進展,包括持續擴大 Renuvion 技術的臨床適應症並解決安全通報的剩餘限制、提升外科醫師與潛在病患對我們近期取得核准的認知、推進我們的新產品組合,以及強化資產負債表狀況。

  • I'll now take a moment to walk through each of these items in further detail. First and most importantly, we made notable progress on our regulatory strategy to obtain new clinical indications to support our sales and marketing efforts and address the remaining issues outlined in the FDA's original safety communication from March of 2022. In April, we secured a new 510(k) clearance for our Renuvion APR handpiece with an indication for the coagulation of subcutaneous soft tissues following liposuction for aesthetic body contouring.

    我現在花點時間更詳細說明上述各項。首先也是最重要的,我們在法規策略上取得顯著進展,透過取得新的臨床適應症來支持我們的銷售與行銷工作,並解決 FDA 於 2022 年 3 月原始安全通報中所列的剩餘問題。4 月,我們為 Renuvion APR 手柄取得新的 510(k) 核准,適應症為在抽脂後用於美學體態雕塑之皮下軟組織凝固(coagulation)。

  • As we shared on our last call, we believe this clearance is significant for 2 primary reasons. First, we believe it directly address the remaining limitations of the FDA safety communication, which initially stated that Renuvion APR handpiece had not been cleared for the use in combination with liposuction. And second, with this specific indication, our Renuvion APR handpiece is now the only device on the market with a 510(k) clearance for use following liposuction.

    如同我們在上次電話會議中分享的,我們認為此項核准之所以重要,主要有兩個原因。第一,我們認為它直接回應了 FDA 安全通報的剩餘限制;該通報最初指出 Renuvion APR 手柄尚未獲准與抽脂合併使用。第二,基於此一特定適應症,我們的 Renuvion APR 手柄目前是市場上唯一在抽脂後使用取得 510(k) 核准的裝置。

  • With this as a backdrop on May 10, the FDA updated the safety communication. The update informed consumers and health care providers about the latest 510(k) clearance, revise the FDA's recommendations related to the use of our product accordingly and outlined the 4 new clinical indications that we have secured for our Renuvion products since the safety communication was originally posted. It has been a little over 3 months since the FDA update to the safety communication was posted and we continue to believe it addressed the remaining issues set forth in the original safety communication from March 14, 2022.

    在此背景下,FDA 於 5 月 10 日更新了安全通報。該更新向消費者與醫療照護提供者說明最新的 510(k) 核准,並據此修訂 FDA 對我們產品使用的建議,同時概述自安全通報最初發布以來,我們已為 Renuvion 產品取得的 4 項新臨床適應症。自 FDA 發布安全通報更新至今已略超過 3 個月,我們仍相信該更新已處理 2022 年 3 月 14 日原始安全通報中所提出的剩餘問題。

  • Since May 10, our efforts have been squarely focused on raising awareness of these recent developments among existing and potential customers. Our team worked quickly to update our sales and marketing materials accordingly and educate our reps, distributors and surgeon customers to effectively communicate these developments and their significance. We also leveraged our presence at recent medical meetings, including the Vegas Cosmetic Surgery and the aesthetic show conferences in June to raise awareness in the industry. While it takes time to bring current and potential customers up to speed on our new 510(k) clearances and the resulting FDA updates, we believe this news is being well-received by the surgeon community and we look forward to building on our recent progress.

    自 5 月 10 日以來,我們的工作重點一直放在提升既有與潛在客戶對這些最新進展的認知。我們的團隊迅速更新相應的銷售與行銷資料,並教育我們的業務代表、經銷商與外科醫師客戶,以有效傳達這些進展及其重要性。我們也運用近期醫學會議的參與機會,包括 6 月的 Vegas Cosmetic Surgery 與 the aesthetic show 研討會,以提升業界認知。雖然讓現有與潛在客戶充分了解我們新的 510(k) 核准以及隨之而來的 FDA 更新需要時間,但我們相信這項消息在外科醫師社群中獲得良好回響,我們也期待在近期進展的基礎上持續推進。

  • In addition to commercializing our Apyx One console, which I discussed earlier, we continue to drive progress with respect to our new product pipeline. On June 14, we were pleased to announce the receipt of 510(k) clearance for our Renuvion micro handpiece with an indication for the delivery of radio frequency energy and/or helium plasma where coagulation or contraction of soft tissue, including subcutaneous tissue is needed. The Renuvion micro handpiece features a smaller instrument shaft, which is half the width of our Renuvion APR handpiece. It's designed to complement our existing product offering by providing surgeons with a new option to achieve soft tissue contraction in cases that may benefit from the use of a smaller profile handpiece.

    除了商業化我們先前提到的 Apyx One 主機之外,我們也持續推動新產品管線的進展。6 月 14 日,我們很高興宣布,我們的 Renuvion micro 手持器已取得 510(k) 核准,適應症為在需要凝固或收縮軟組織(包括皮下組織)時,提供射頻能量及/或氦電漿。Renuvion micro 手持器具備更小的器械軸身,寬度僅為我們 Renuvion APR 手持器的一半。其設計旨在補強我們既有的產品組合,為外科醫師提供新的選擇,在可能受益於較小外形手持器的情況下達成軟組織收縮。

  • It's also worth noting that our Renuvion micro handpiece is designed exclusively for use with our Apyx One console, providing another compelling reasons for surgeons to update to our latest generation system. After securing 510(k) clearance, our team has been focused on preparing to commence our limited market release of the Renuvion micro handpiece during the third quarter.

    同時也值得注意的是,Renuvion micro 手持器專為搭配我們的 Apyx One 主機使用而設計,這也為外科醫師升級至我們最新一代系統提供了另一項具吸引力的理由。在取得 510(k) 核准後,我們的團隊一直專注於準備在第三季開始 Renuvion micro 手持器的有限市場上市。

  • I'm pleased to announce today that we have commenced our limited market release at the end of July. During the limited market release phase, we look forward to gaining important feedback from a select group of our existing surgeon users to inform our full commercial launch, which we are targeting for the fourth quarter of this year. And finally, in the second quarter, we continued to improve our operating efficiency while securing additional capital to enhance our balance sheet condition. We were pleased to deliver stronger-than-expected margin, operating leverage and cash flow from operations performance in the second quarter despite the softer-than-expected total revenue results.

    我很高興在今天宣布,我們已於 7 月底啟動有限市場上市。在有限市場上市階段,我們期待從一小群既有外科醫師使用者取得重要回饋,以作為我們完整商業上市的參考;我們目標是在今年第四季全面上市。最後,在第二季,我們在提升營運效率的同時,也取得額外資金以強化資產負債表狀況。儘管總營收結果低於預期,我們仍在第二季交出優於預期的毛利率、營運槓桿與營運現金流表現。

  • We continue to focus our investments on the highest priority areas to maximize our capital and drive improvements in our operating loss. Specifically, excluding the $2.7 million gain from our sale leaseback transaction, we delivered a $2 million reduction in operating loss year-over-year in Q2. We expect improvements in operating losses over the balance of 2023 as well. May 8th, we completed the sale-leaseback transaction for our Clearwater property, which provided us net proceeds of $6.6 million.

    我們持續將投資聚焦於最優先的領域,以最大化資本效益並推動營運虧損改善。具體而言,若排除售後租回交易帶來的 270 萬美元收益,我們在第二季的營運虧損較去年同期減少 200 萬美元。我們也預期 2023 年剩餘期間的營運虧損將持續改善。5 月 8 日,我們完成了 Clearwater 物業的售後租回交易,為我們帶來 660 萬美元的淨收益。

  • And lastly, I'm excited to announce that actually today, we received an $8.1 million payment from the Internal Revenue Service for the cash refunds that they had approved at the beginning of this year. This $8.1 million refund payment included $7.7 million of refunds and $400,000 of related interest. With these cash tax refunds and potential capacity under our credit agreement and $18.5 million of cash on our balance sheet at the end of the second quarter, we remain confident that we have the adequate capital and borrowing capacity to support our near-term operations and growth initiatives as we work towards our longer-term goals of achieving sustainable profitability and strong free cash flow generation.

    最後,我很興奮地宣布,就在今天,我們已收到美國國稅局(Internal Revenue Service)支付的 810 萬美元款項,這是其在今年年初核准的現金退稅。這筆 810 萬美元的退稅款包含 770 萬美元的退稅以及 40 萬美元的相關利息。憑藉這些現金退稅、我們信貸協議下的潛在可用額度,以及截至第二季末資產負債表上的 1,850 萬美元現金,我們仍有信心具備充足的資本與借款能力,以支持近期營運與成長計畫,同時朝向更長期的目標邁進,包括達成可持續的獲利能力與強勁的自由現金流創造。

  • I'll now turn it over to Tara to review the second quarter financial results and 2023 guidance, which we updated in today's press release. Tara?

    接下來我把時間交給 Tara,請她回顧第二季財務結果以及我們在今天新聞稿中更新的 2023 年財測指引。Tara?

  • Tara H. Semb - CFO, Treasurer & Secretary

    Tara H. Semb - CFO, Treasurer & Secretary

  • Thanks, Charlie. I will begin my review of our second quarter financial performance at the gross profit line since Charlie covered our revenue results. Gross profit for the second quarter of 2023 increased $2.4 million or 34% year-over-year to $9.3 million. Gross profit margin was 68.4% compared to 67.2% in the prior year period. The increase in our gross margin was driven primarily by changes in the sales mix between our 2 segments, with our Advanced Energy segment comprising a higher percentage of total sales and within our Advanced Energy segment both by product and by geography as compared to the second quarter of 2022.

    謝謝,Charlie。由於 Charlie 已說明我們的營收結果,我將從毛利開始回顧第二季的財務表現。2023 年第二季毛利較去年同期增加 240 萬美元(增幅 34%)至 930 萬美元。毛利率為 68.4%,相較於去年同期的 67.2%。毛利率上升主要受兩大事業部門銷售組合變化所帶動,其中 Advanced Energy 部門占總銷售的比重提高;此外,在 Advanced Energy 部門內,無論按產品或按地區的組合,相較 2022 年第二季亦有所變化。

  • Operating expenses increased $0.3 million or 2.5% year-over-year. The increase in operating expenses year-over-year was primarily driven by an increase in SG&A expenses of $0.8 million and salaries and related costs and R&D expenses, which both increased by $0.1 million. These items were partially offset by a $0.8 million decrease in professional services expenses. Loss from operations decreased $4.7 million or 79% year-over-year to $1.2 million. Included in the loss from operations is the $2.7 million gain from our sale-leaseback transaction that occurred this period. Excluding the gain from our sale-leaseback transaction, our loss from operations decreased $2 million or 34% year-over-year to $3.9 million.

    營業費用較去年同期增加 30 萬美元(增幅 2.5%)。營業費用年增主要來自 SG&A 費用增加 80 萬美元,以及薪資與相關成本與研發費用各增加 10 萬美元。上述項目部分被專業服務費用減少 80 萬美元所抵銷。營業損失較去年同期減少 470 萬美元(降幅 79%)至 120 萬美元。營業損失中包含本期售後租回交易帶來的 270 萬美元收益。若排除售後租回交易收益,營業損失較去年同期減少 200 萬美元(降幅 34%)至 390 萬美元。

  • Total other income net was $282,000 compared to $622,000 last year. The change in total other income net was driven by an increase in net interest expense related to the outstanding debt obligations on our term loan in the second quarter of 2023 compared to no outstanding borrowing in the prior year period. Net loss attributable to stockholders decreased $4.4 million or 82% year-over-year to $1 million or $0.03 per share compared to $5.4 million or $0.16 per share for the second quarter of 2022. Excluding our nonrecurring gain, non-GAAP net loss attributable to stockholders decreased $1.7 million or 32% year-over-year. Adjusted EBITDA loss decreased $1.8 million or 53% year-over-year to $1.6 million compared to $3.4 million in the prior year period. As a reminder, we provided a detailed reconciliation from net loss attributable to stockholders to non-GAAP adjusted EBITDA in our earnings press release today.

    其他收益淨額合計為 28.2 萬美元,去年為 62.2 萬美元。其他收益淨額的變動主要是因 2023 年第二季定期貸款未償債務義務所產生的淨利息費用增加;而去年同期並無未償借款。歸屬於股東的淨損較去年同期減少 440 萬美元(降幅 82%)至 100 萬美元,或每股 0.03 美元;相較之下,2022 年第二季為 540 萬美元,或每股 0.16 美元。若排除一次性收益,歸屬於股東的非 GAAP 淨損較去年同期減少 170 萬美元(降幅 32%)。調整後 EBITDA 損失較去年同期減少 180 萬美元(降幅 53%)至 160 萬美元,去年同期為 340 萬美元。提醒各位,我們已在今日的財報新聞稿中提供從歸屬於股東的淨損到非 GAAP 調整後 EBITDA 的詳細調節表。

  • Cash used in operations for the 3 months ending June 30 was $4.9 million compared to $5.9 million in the prior year period, driven by the year-over-year improvement in net loss, offset partially by the gain on sale and higher use of cash and working capital compared to the second quarter of 2022. As of June 30, 2023, the company had cash and cash equivalents of $18.5 million compared to $10.2 million as of December 31, 2022. As Charlie mentioned, today we received an $8.1 million payment from the Internal Revenue Service for the cash tax refunds they approved at the beginning of this year. This $8.1 million refund payment includes $7.7 million of refunds and $400,000 of related interest.

    截至 6 月 30 日止三個月,營運活動使用現金為 490 萬美元,去年同期為 590 萬美元;主要受淨損年減改善所帶動,但部分被出售收益以及相較 2022 年第二季更高的現金與營運資金使用所抵銷。截至 2023 年 6 月 30 日,公司持有現金及約當現金 1,850 萬美元,較 2022 年 12 月 31 日的 1,020 萬美元增加。如 Charlie 所提及,我們今天收到美國國稅局支付的 810 萬美元款項,係其在今年年初核准的現金退稅。這筆 810 萬美元的退稅款包含 770 萬美元的退稅以及 40 萬美元的相關利息。

  • Turning to a review of our 2023 financial guidance, which we reaffirmed in our earnings press release today. For the 12 months ending December 31, 2023, we continue to expect total revenue in the range of $59 million to $62 million, representing growth of approximately 33% to 39% year-over-year. Our total revenue guidance range continues to assume Advanced Energy revenue in the range of $51 million to $54 million and OEM revenue of approximately $8 million. In terms of our profitability guidance for the full year 2023, we continue to expect net loss attributable to stockholders of approximately $10.5 million.

    接著回顧我們 2023 年財務指引;我們已在今日的財報新聞稿中再次確認。就截至 2023 年 12 月 31 日止 12 個月而言,我們仍預期總營收介於 5,900 萬至 6,200 萬美元,約較去年同期成長 33% 至 39%。我們的總營收指引區間仍假設 Advanced Energy 營收介於 5,100 萬至 5,400 萬美元,OEM 營收約 800 萬美元。就 2023 年全年獲利能力指引而言,我們仍預期歸屬於股東的淨損約為 1,050 萬美元。

  • Our formal financial guidance for 2023 incorporates the following considerations for modeling purposes. First, we expect gross margins of approximately 66.5% to 67.5%, up roughly 100 basis points versus our prior guidance assumptions.

    我們 2023 年正式財務指引納入以下建模考量。第一,我們預期毛利率約為 66.5% 至 67.5%,較先前指引假設上調約 100 個基點。

  • Second, we now expect low to mid-single-digit growth in operating expenses year-over-year. Third, we expect total other expense net of approximately $900,000 in 2023 compared to our prior expectation of income of approximately $1.4 million. The change versus prior guidance is driven by the updated treatment on the gain on our sale-leaseback, which we recognized in GAAP operating loss in the second quarter compared to our prior full year 2023 guidance, which assumed it would be recognized in total other expense net. Note our updated guidance for total other expense net in 2023 now assumes interest expense net of approximately $1.6 million compared to $1.7 million previously.

    第二,我們目前預期營業費用年增為低至中個位數百分比。第三,我們預期 2023 年其他費用淨額合計約為 90 萬美元,而先前預期為其他收益約 140 萬美元。相較先前指引的變動,主要來自售後租回收益的更新會計處理:我們在第二季將其認列於 GAAP 營業損失中;而先前 2023 年全年指引假設其將認列於其他費用淨額合計。請注意,我們更新後的 2023 年其他費用淨額合計指引,現假設淨利息費用約為 160 萬美元,先前為 170 萬美元。

  • Fourth, we now expect non-controlling interests of approximately $180,000 compared to $150,000 previously. And lastly, our guidance for 2023 now assumes an income tax benefit of approximately $2 million, noncash depreciation and amortization of approximately $0.7 million, noncash stock-based compensation expense of $5.6 million and weighted average diluted shares outstanding of approximately 34.8 million shares. For the third quarter of 2023, we anticipate total revenue in the range of $15 million to $16 million, driven by an increase in Advanced Energy sales in the range of approximately 65% to 76% year-over-year, offset partially by a decrease in OEM sales of approximately 7% year-over-year.

    第四,我們目前預期非控股權益約為 18 萬美元,先前為 15 萬美元。最後,我們對 2023 年的指引目前假設:所得稅利益約 200 萬美元、非現金折舊與攤銷約 70 萬美元、非現金股票基礎給付薪酬費用 560 萬美元,以及加權平均稀釋後流通在外股數約 3,480 萬股。對於 2023 年第三季,我們預期總營收介於 1,500 萬至 1,600 萬美元,主要由先進能源(Advanced Energy)銷售年增約 65% 至 76% 所帶動,但部分被 OEM 銷售年減約 7% 所抵銷。

  • Lastly, our formal guidance for 2023 continues to assume we end the year with approximately $20 million in cash and cash equivalents on our balance sheet as of 12/31/2023.

    最後,我們對 2023 年的正式指引仍假設截至 2023/12/31,我們資產負債表上的現金及約當現金約為 2,000 萬美元。

  • With that, I'll turn the call back to Charlie for closing remarks.

    接下來,我把電話交回 Charlie 作結語。

  • Charles D. Goodwin - President, CEO & Director

    Charles D. Goodwin - President, CEO & Director

  • Thanks, Tara. In conclusion, we are very pleased with our strong U.S. sales performance during the second quarter, which enabled us to deliver 40% year-over-year growth in our Advanced Energy business coupled with notable year-over-year improvements in our operating loss. From an operational standpoint, we secured a new 510(k) clearance to address the FDA safety communication and improve our positioning in the market while continuing to raise awareness of our technologies, expand our product offering and enhance our balance sheet. Having addressed the remaining issues in the safety communication, we have seen subsequent improvements in the U.S. sales environment for our Advanced Energy generators and we expect continued improvement globally over the balance of the year.

    謝謝你,Tara。總結來說,我們對第二季美國市場強勁的銷售表現感到非常滿意,這使我們的先進能源業務實現年增 40% 的成長,同時營運虧損也較去年同期明顯改善。從營運角度來看,我們取得新的 510(k) 核准,以回應 FDA 的安全通報並改善我們在市場上的定位,同時持續提升市場對我們技術的認知、擴充產品供應並強化資產負債表。在解決安全通報中剩餘問題後,我們看到美國市場對我們先進能源產生器的銷售環境隨後有所改善,並預期在今年剩餘期間全球也將持續改善。

  • We are reaffirming our guidance today based on our recent progress and continued confidence in the ability to deliver Advanced Energy sales growth in excess of 38% year-over-year, combined with significant reductions in our net loss in 2023. We believe our growth in the second half of 2023 will continue to benefit from multiple tailwinds, including the 4 510(k) clearances we obtained for specific clinical indications in 2022 and 2023, along with the most recent update made to the safety communication.

    基於近期進展以及我們對於在 2023 年實現先進能源銷售年增超過 38% 的能力持續有信心,並結合 2023 年淨虧損大幅下降,我們今天重申指引。我們認為 2023 年下半年成長將持續受多項利多推動,包括我們在 2022 年與 2023 年針對特定臨床適應症取得的 4 項 510(k) 核准,以及近期對安全通報所做的最新更新。

  • U.S. commercialization of our Apyx One console and our efforts to raise awareness of our technologies at both the provider and consumer levels, including our direct-to-consumer initiatives. And in addition to driving strong growth in the second half of this year, we remain focused on delivering against our remaining strategic initiatives that we outlined at the beginning of the year, enhancing our Renuvion product portfolio by bringing new technologies to market, expanding our portfolio of clinical evidence supporting the use of our products and managing our expenses while driving progress towards profitability.

    我們在美國推動 Apyx One 主機(console)的商業化,以及在醫療提供者與消費者層面提升對我們技術的認知之努力,包括我們的直接面向消費者(direct-to-consumer)計畫。此外,除了在今年下半年推動強勁成長外,我們仍專注於落實年初所提出的其餘策略性計畫:透過將新技術推向市場來強化 Renuvion 產品組合、擴充支持我們產品使用的臨床證據組合,以及在推動邁向獲利的同時管理費用。

  • By continuing to achieve progress across all of these fronts, we are committed to positioning Apyx Medical for the future so we can continue to expand our share of the multibillion-dollar opportunity that lies ahead for our Renuvion technology in the global cosmetic surgery market.

    透過在上述各方面持續取得進展,我們致力於為 Apyx Medical 的未來做好定位,以便在全球醫美手術市場中,持續擴大我們在 Renuvion 技術所面臨之數十億美元機會中的市占率。

  • I'd like to close by thanking our team and distributor partners for their contributions this past quarter as well as our customers, investors and everyone on today's call for their interest and support for our mission.

    最後,我要感謝我們的團隊與經銷夥伴在本季的貢獻,也感謝我們的客戶、投資人,以及今天電話會議上的所有與會者對我們使命的關注與支持。

  • With that, operator, let's now open the call for questions.

    那麼,接下來請接線員開放提問。

  • Operator

    Operator

  • (Operator Instructions) And our first question will come from the line of Matthew O'Brien with Piper Sandler.

    (接線員指示)我們的第一個問題來自 Piper Sandler 的 Matthew O'Brien。

  • Phillip Paul Dantoin - Research Analyst

    Phillip Paul Dantoin - Research Analyst

  • This is Phil on for Matt. I guess just to start, what was the magnitude of the international softness in the quarter? Understanding the stocking dynamic you called out, but what gives you confidence international kind of return to a source of growth? And just to tack on, one, you called out pockets of weakness versus strength in certain geographies. Can you speak to the differences in those individual markets that might be driving those differences?

    我是 Phil,代 Matt 提問。我想先問,本季國際市場疲弱的幅度有多大?我理解你提到的備貨(stocking)動態,但是什麼讓你有信心國際市場會回到成長來源?另外再追問一點,你提到某些地區有疲弱、某些地區有強勁。你能談談各個市場之間的差異,以及可能驅動這些差異的因素嗎?

  • Charles D. Goodwin - President, CEO & Director

    Charles D. Goodwin - President, CEO & Director

  • Yes. Just let me take a step back for a minute. We saw some really positive developments in our business in Q2. So I want to make sure that everybody understands that we feel really good about where we are. We obtained the 510(k) clearance for Renuvion following liposuction and saw the communication update from the safety notice as we had expected. And we also saw significant improvements in our Advanced Energy sales performance, which increased 21% quarter-over-quarter and 40% year-over-year. Our U.S. Advanced Energy sales growth and OUS generator sales growth were consistent with our expectations. So those were right what we expected.

    好的。讓我先退一步說明。我們在第二季看到業務出現一些非常正面的發展,所以我想確保大家理解我們對目前的狀況感覺非常好。我們取得了 Renuvion 在抽脂後使用的 510(k) 核准,並如我們預期看到安全通知的通報更新。我們也看到先進能源銷售表現顯著改善,季增 21%、年增 40%。我們在美國的先進能源銷售成長以及美國以外(OUS)的產生器銷售成長都符合我們的預期,所以這些都正如我們所預期。

  • Our OUS handpiece sales were lower than we had expected, largely due to the timing of some distribution orders. And I'm not going to get into details other than to say that it was not a single distributor and that we expect those orders in the back half of 2023. And that's one of the reasons why we're reaffirming our guidance today and we feel good about our stated growth objectives or expectations for the full year and Q3.

    我們在 OUS 的手把(handpiece)銷售低於預期,主要是因為部分經銷訂單的時間點所致。我不會深入細節,只能說並非單一經銷商造成,而且我們預期這些訂單會在 2023 年下半年出現。這也是我們今天重申指引的原因之一,我們對於全年以及第三季所陳述的成長目標或預期感到樂觀。

  • Phillip Paul Dantoin - Research Analyst

    Phillip Paul Dantoin - Research Analyst

  • And I guess just to talk a bit about the micro handpiece. What lift can you expect out of that device this year? How big of a deal is that smaller instrument shaft? And how should we think about the interest here as a lift to the Apyx One console?

    另外想談談 micro 手把。你預期今年這個裝置能帶來多大的拉抬?較小的器械軸身有多重要?以及我們應該如何看待市場興趣對 Apyx One 主機帶來的帶動效果?

  • Charles D. Goodwin - President, CEO & Director

    Charles D. Goodwin - President, CEO & Director

  • Yes. So remember, as I outlined in the remarks, we have just started our soft launch in Q3. And so right now the device is in hands with some of our top surgeon customers and they're using it and we're gaining feedback where we will develop the safe and effective use guidelines and we have all the information that we need to start to roll out of that in the fourth quarter, okay?

    好的。如同我在談話中提到的,我們在第三季才剛開始進行軟性上市(soft launch)。因此目前這個裝置已交到我們一些頂尖外科醫師客戶手上,他們正在使用,我們也在蒐集回饋;接著我們會制定安全且有效使用的指引,並取得在第四季開始推廣所需的所有資訊,好嗎?

  • And the thing that is important about that, the micro handpiece and the smaller size of it is now it can go into areas where doctors wanted something smaller and didn't want to take the existing APR in there. And so think about places like the fine areas of the face, think about the hands, think about the knees, think about the ankles, think about smaller areas where people still want some form of skin contraction. And so we believe this will be a nice addition to our portfolio.

    而這點的重要性在於,micro 手把及其較小尺寸,現在可以進入醫師希望更小、且不想把既有 APR 放進去的部位。你可以想像像是臉部精細區域、手部、膝蓋、腳踝等較小部位,這些地方人們仍希望有某種皮膚收縮效果。因此我們相信這會是我們產品組合的一項很好的補充。

  • And the other thing to keep in mind with this too is the micro handpiece if you're going to use that, it requires an upgrade to the Apyx One console. And so we will start to see some of that benefit of the micro handpiece itself in the fourth quarter, but it's really more going to have an impact in 2024.

    另外也要記住,若要使用 micro 手把,需要對 Apyx One 主機進行升級。因此我們會在第四季開始看到 micro 手把本身帶來的一些效益,但它真正更大的影響會在 2024 年。

  • Operator

    Operator

  • Our next question comes from the line of Matt Hewitt with Craig-Hallum.

    下一個問題來自 Craig-Hallum 的 Matt Hewitt。

  • Matthew Gregory Hewitt - Senior Research Analyst

    Matthew Gregory Hewitt - Senior Research Analyst

  • Maybe first off, regarding Apyx One, maybe what's the feedback been from customers? I realize it's still relatively early days, but what has been the conversion rate of your existing users so far?

    首先關於 Apyx One,客戶回饋如何?我知道目前仍算早期,但到目前為止,你們既有用戶的轉換率如何?

  • Charles D. Goodwin - President, CEO & Director

    Charles D. Goodwin - President, CEO & Director

  • Yes. The initial response that we've seen for the Apyx One launch has been positive and it's been an important driver for us so far in Q2 of '23. The feedback has been highlighted by the advanced features, which is the touchscreen user phase, the presets for bodies and different procedures and the cloud connectivity functionality, which has really proven to be very important because a lot of the doctors were having their staff record this stuff and the amount of gas and the amount of usage and the amount of jewels, they were recording all this stuff manually on the patient's chart and now they can just upload this and the generator will do that automatically.

    好的。我們看到 Apyx One 上市初期的反應是正面的,而且在 2023 年第二季迄今也一直是我們的重要驅動因素。回饋主要聚焦在其進階功能,包括觸控螢幕使用者介面、針對身體部位與不同手術的預設模式,以及雲端連線功能。這點被證明非常重要,因為許多醫師原本需要讓員工記錄這些資訊,例如氣體用量、使用量、焦耳數等,他們過去都要手動記在病患病歷上;現在只要上傳,產生器就能自動完成。

  • And so that's been a really nice feature. And we're really happy with the way it's been resonating with the surgeons and we expect it to remain an important contributor for us for the second half of the year, too.

    因此這是一個非常好的功能。我們也很高興它在外科醫師間引起共鳴,並預期它在今年下半年也會持續成為我們的重要貢獻來源。

  • Matthew Gregory Hewitt - Senior Research Analyst

    Matthew Gregory Hewitt - Senior Research Analyst

  • And then shifting a little bit here. But regarding the international handpiece sales, I understand it's a timing-related issue. If I heard you correctly, it sounds like it's more back half. So does that imply we shouldn't anticipate that bouncing back here in Q3, it's going to take a little bit longer? Or maybe have you received some orders already here in Q3 from international, these specific international distributors? Any additional color there would be helpful.

    接著稍微轉換一下話題。關於國際手把銷售,我理解這是時間點相關的問題。如果我沒聽錯,你的意思是會在下半年回補。那是否代表我們不應預期第三季就會反彈,而是需要更久一些?或者你們在第三季是否已經收到一些來自國際、這些特定國際經銷商的訂單?如果能提供更多細節會很有幫助。

  • Charles D. Goodwin - President, CEO & Director

    Charles D. Goodwin - President, CEO & Director

  • Yes. Look, I think the important thing to know about that is it was just some orders, some handpieces. It wasn't one distributor and we expect those orders in the back half of this year. And I think that's all the detail that we're going to give on that. And that's why reaffirmed our guidance for the back half of the year because we're confident that we're going to get those in the back half of the year.

    是的。你看,我認為關於這件事需要知道的重要一點是,那只是一些訂單、一些手柄(handpieces)。並不是某一家經銷商的單一訂單,我們預期這些訂單會在今年下半年到位。我想我們就只會提供到這些細節。也正因如此,我們重申了對今年下半年的指引,因為我們有信心會在今年下半年收到這些訂單。

  • Operator

    Operator

  • Our next question comes from the line of George Sellers with Stephens.

    我們的下一個問題來自 Stephens 的 George Sellers。

  • George Stone Sellers - Research Analyst

    George Stone Sellers - Research Analyst

  • Maybe to start with the quarter. I'm just curious if you could give some detail on how utilization trended with liposuction versus standalone? And if that trend changed following the FDA clearance?

    也許先從本季開始。我只是好奇你們能否提供一些細節,說明抽脂(liposuction)搭配使用與單獨使用(standalone)的使用率(utilization)趨勢如何?以及在 FDA 核准(clearance)之後,這個趨勢是否有改變?

  • Charles D. Goodwin - President, CEO & Director

    Charles D. Goodwin - President, CEO & Director

  • Yes. I don't know that I can speak to that with any trend data or anything else. I mean remember that the FDA safety communication was just updated in the middle of May and we basically had 6 weeks of time in the quarter where that was behind us. And so in terms of monthly tens or specificity there, we did call out a notable uptick in the U.S. adoption after the safety communication in May. So the only thing that I can tell you is that after that was out there that we started to have a much greater rate of adoption than we did before or after that. And so that obviously has us very encouraged for the rest of the year.

    是的。我不確定我是否能用任何趨勢數據或其他資料來談這件事。我的意思是,請記得 FDA 的安全通報(safety communication)是在 5 月中旬才更新,而在本季中,我們基本上只有 6 週的時間是已經度過那段影響。因此,就月度趨勢或更具體的細節而言,我們確實提到在 5 月安全通報之後,美國市場的採用率有明顯上升。所以我唯一能告訴你的是,在那個通報發布之後,我們的採用速度比之前要高得多。這也讓我們對今年剩餘時間感到非常鼓舞。

  • George Stone Sellers - Research Analyst

    George Stone Sellers - Research Analyst

  • And maybe switching to guidance here. You obviously reiterated your revenue guidance, but raised the gross profit expectations. I'm just curious if you could give a little bit more detail. Is there some change maybe in the contribution you're expecting from international versus the U.S.? Or if you could just give a little bit more detail? Maybe that would be helpful.

    那也許切換到指引。你們顯然重申了營收指引,但上調了毛利預期。我只是好奇你們能否提供更多細節。是否是你們對國際市場相對於美國市場的貢獻預期有所改變?或者如果能再多提供一些細節,可能會很有幫助。

  • Charles D. Goodwin - President, CEO & Director

    Charles D. Goodwin - President, CEO & Director

  • Yes. So I mean, really, it's primarily driven by mix assumptions and it is favorable mix within our Advanced Energy segment by geography and by product.

    是的。所以我的意思是,主要是由產品組合(mix)假設所驅動,而且是在我們先進能源(Advanced Energy)部門中,按地理區域與按產品來看,都是更有利的組合。

  • Operator

    Operator

  • (Operator Instructions) Our next question comes from the line of Frank Takkinen with Lake Street Capital Markets.

    (接線員指示)我們的下一個問題來自 Lake Street Capital Markets 的 Frank Takkinen。

  • Frank James Takkinen - Senior Research Analyst

    Frank James Takkinen - Senior Research Analyst

  • I was hoping to ask one on the guide as well. I was hoping you could parse out a couple of pieces to the growth expectation. The primary question I want to ask is just how are you thinking about growth in handpieces versus console, which do you expect to be growing faster? Or is it kind of broad-based strength amongst both?

    我也想問一個關於指引的問題。我希望你們能把成長預期拆解成幾個部分。我主要想問的是,你們如何看待手柄(handpieces)相對於主機/控制台(console)的成長?你們預期哪一個會成長更快?還是兩者都呈現廣泛的強勁表現?

  • Charles D. Goodwin - President, CEO & Director

    Charles D. Goodwin - President, CEO & Director

  • Yes. Look, we had growth both in generators and in handpieces globally, right? And we had that for the quarter that we just had, where we had faster growth and more growth was the adoption of new generators and specifically in the U.S., but also outside the U.S. And we expect that to remain really strong in the back half of the year and that is part of the momentum that we had. And we've got that, especially in the U.S. because of multiple tailwinds. We've got the indications that we've talked about. We've got the reduced headwinds now that the FDA updated the safety notice. We've got the Apyx One generator, which right now, remember, is only launched in the United States. So that is a U.S. thing in particular.

    是的。你看,我們在全球的發電機(generators)與手柄都實現了成長,對吧?而且在剛結束的這一季也是如此;其中成長更快、成長更多的是新發電機的採用,特別是在美國,但在美國以外也有。我們預期這在今年下半年仍會非常強勁,這也是我們所擁有的動能之一。尤其是在美國,因為有多重順風因素:我們有先前談到的適應症(indications);FDA 更新安全通知後,逆風也減少了;我們還有 Apyx One 發電機——請記得,目前它只在美國上市,所以這特別是美國的因素。

  • And right now our direct-to-consumer marketing is only in the United States, too. And so we expect the U.S. to be a bigger driver. If the U.S. is the bigger driver that means that our gross margins go up, that there is a positive impact on our gross margins.

    而且目前我們的直面消費者(direct-to-consumer)行銷也只在美國進行。因此我們預期美國會成為更大的驅動力。如果美國是更大的驅動力,就意味著我們的毛利率會上升,對毛利率會有正面影響。

  • Frank James Takkinen - Senior Research Analyst

    Frank James Takkinen - Senior Research Analyst

  • And then maybe for my second one. I want to ask on Ozempic. Obviously, it's been a hot topic in all headlines recently. Curious if you could kind of illustrate or explain how you think that could positively or negatively impact your business in the future?

    那麼也許我的第二個問題。我想問關於 Ozempic。顯然,最近它在各大新聞標題中都是熱門話題。想請你們說明或解釋一下,你們認為它未來可能如何對你們的業務產生正面或負面影響?

  • Charles D. Goodwin - President, CEO & Director

    Charles D. Goodwin - President, CEO & Director

  • Yes. The first thing is, is that we see it as a tremendous tailwind to our business. We think it is going to be very positive for our company. The thing that I want to make sure that everybody understands is this is just playing out right now and just getting started in real time. And we are working with some of our clinicians that are actually doing this. They're actually marketing the skinny shots and they've got a whole program for people to come in and lose weight and then be able to take care of their slack skin after.

    是的。第一點是,我們把它視為對我們業務非常強勁的順風。我們認為這將對公司非常正面。我想確保大家理解的是:這件事現在才正在即時發展中,而且才剛開始。我們正在與一些實際在做這件事的臨床醫師合作——他們確實在行銷所謂的瘦身針(skinny shots),並且有一整套方案,讓人們進來減重,之後再處理鬆弛的皮膚。

  • And remember, for us, we've got an indication for use of liposuction, but we've also got the indication for just for soft tissue contraction. And we really don't care how the skin gets black. What we care about is that people don't like black skin and they want to get it treated, and Renuvion still is the best technology in the marketplace today to treat that black skin. And so for us, it's a tremendous benefit. It's a tremendous benefit that we think is going to continue for many years to come, quite frankly.

    而且請記得,對我們而言,我們有抽脂用途的適應症,但我們也有單純用於軟組織收縮(soft tissue contraction)的適應症。我們其實不在乎皮膚是怎麼變鬆的;我們在乎的是人們不喜歡鬆弛的皮膚,並且想要治療,而 Renuvion 仍然是目前市場上治療鬆弛皮膚的最佳技術。所以對我們來說,這是巨大的利多。我們坦白說認為這樣的利多會持續很多年。

  • Frank James Takkinen - Senior Research Analyst

    Frank James Takkinen - Senior Research Analyst

  • Maybe I'll squeak one more in here. With the FDA notice that came shortly after the liposuction 510(k), I think there was an inference in there related to the FDA enforcing on-label usage across the industry. Have you seen this play out at all in the field as it relates to your competition? Or is this something that hasn't come to fruition yet?

    也許我再塞最後一個問題。FDA 在抽脂 510(k) 之後不久發布的通知中,我認為其中暗示 FDA 會在整個產業推動並執行標示適應症(on-label)使用。你們在第一線是否看到這件事在競爭對手那邊有任何落實?還是說這件事目前還沒有真正發生?

  • Charles D. Goodwin - President, CEO & Director

    Charles D. Goodwin - President, CEO & Director

  • Yes. Unfortunately, we have not seen any sign of that. There are still people that are making claims that they shouldn't make and doing things that they shouldn't be doing. So as of right now we really have not seen any evidence of that, even though it was -- you are correct. It was stated in the safety notice that they were going to do that. But in fairness to the FDA, that safety notice did just come out on May 10. And so we are not that far away from that still, so.

    是的。不幸的是,我們沒有看到任何這方面的跡象。仍然有人在做不該做的宣稱,以及做不該做的事情。所以截至目前,我們確實沒有看到任何證據,儘管——你說得沒錯——安全通知中確實提到他們會這麼做。但公平地說,FDA 的那份安全通知是在 5 月 10 日才發布,所以距離現在也還不算太久。

  • Operator

    Operator

  • Our next question is from Matt Hewitt with Craig-Hallum.

    我們的下一個問題來自 Craig-Hallum 的 Matt Hewitt。

  • Matthew Gregory Hewitt - Senior Research Analyst

    Matthew Gregory Hewitt - Senior Research Analyst

  • Just a follow-up regarding the OUS opportunity. I realize you have a lot on your plate at the moment. But are you still seeking other incremental OUS approvals? I believe there's been a few countries in the past that you talked about potentially going after. I'm just curious if those are still in the works.

    關於美國以外(OUS)的機會再追問一下。我知道你們目前手上有很多事情要處理。但你們是否仍在尋求其他額外的 OUS 核准?我記得過去你們提過有幾個國家可能會去申請。我只是好奇這些是否仍在進行中。

  • Charles D. Goodwin - President, CEO & Director

    Charles D. Goodwin - President, CEO & Director

  • Yes, for sure. We did not obtain any new registrations in Q2 and our guidance doesn't assume any contributions for many new countries. But as you mentioned, the 2 big markets that we are not in are South Korea and China. And so we are still pursuing both of those markets. And we look forward to the day that I can tell you that we got clearance in both of those places. So we'll make sure that everybody knows when that happens for sure.

    是的,當然。我們在第二季沒有取得任何新的註冊,而我們的指引也沒有假設會有許多新國家的貢獻。但如你所提到,我們尚未進入的兩個大型市場是南韓與中國。因此我們仍在推進這兩個市場。我也期待有一天能告訴你們,我們在這兩個地方都取得核准(clearance)。所以一旦發生,我們一定會確保讓大家知道。

  • Operator

    Operator

  • We are currently showing no remaining questions at this time. And with that, this does conclude our conference today. Thank you for your participation.

    目前我們顯示沒有剩餘問題。那麼,今天的電話會議到此結束。感謝各位的參與。